Teceleukin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Teceleukin
Accession Number
DB15389
Type
Biotech
Groups
Investigational
Description

Teceleukin is under investigation in clinical trial NCT03610490 (Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic Ductal Adenocarcinoma).

Synonyms
Not Available
External IDs
RO-236019
Categories
Not Available
UNII
H5ZRB188EI
CAS number
136279-32-8

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentClinical Stage IV Cutaneous Melanoma AJCC v8 / Clinical Stage IV Cutaneous Melanoma AJCC v8 (American Joint Committee on Cancer ) / Cutaneous Melanoma, Stage III / Cutaneous Melanoma, Stage IV / IL13RA2 Positive / Metastatic Melanoma / Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 / Pathologic Stage IV Cutaneous Melanoma AJCC v81
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2RecruitingTreatmentHigh Grade Ovarian Serous Adenocarcinoma / Metastatic Colorectal Adenocarcinoma / Oligometastasis / Ovarian Carcinosarcoma / Pancreatic Ductal Adenocarcinoma / Recurrent Colorectal Carcinoma / Recurrent Malignant Neoplasm / Recurrent Osteosarcoma / Recurrent Ovarian Carcinoma / Refractory Colorectal Carcinoma / Refractory Malignant Neoplasm / Refractory Osteosarcoma / Refractory Ovarian Carcinoma / Stage IV Colorectal Cancer AJCC v81
3CompletedTreatmentRecurrent Melanoma / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 09:24 / Updated on March 01, 2020 22:06

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates